iluvien
Generic: fluocinolone acetonide intravitreal implant·Brand: Iluvien
iluvien: developed by 2 companies · 1 FDA decision.
iluvien evidence translation
What we can confirm
1 FDA record
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about iluvien, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS)Diabetic Macular Edema (DME); chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS)
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| ALIMERA SCIENCES INC (ALIM) Non-infectious uveitis affecting the posterior segment of th… | Approved |
| ANI PHARMACEUTICALS INC (ANIP) Diabetic Macular Edema (DME); chronic non-infectious uveitis… | Approved |
Frequently asked questions
Who is developing iluvien?
iluvien is being developed by ALIMERA SCIENCES INC, ANI PHARMACEUTICALS INC.
What is iluvien's latest FDA decision?
The most recent tracked FDA decision for iluvien is Approval, dated September 26, 2014.